| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Novogene Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.44 |
| 52 Week High | CN¥26.60 |
| 52 Week Low | CN¥9.03 |
| Beta | 0.83 |
| 11 Month Change | 22.68% |
| 3 Month Change | 40.60% |
| 1 Year Change | -40.84% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688315 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 6.6% | 10.1% | 6.9% |
| 1Y | -40.8% | -25.0% | 10.3% |
Return vs Industry: 688315 underperformed the CN Life Sciences industry which returned -25% over the past year.
Return vs Market: 688315 underperformed the CN Market which returned 10.3% over the past year.
Price Volatility
| 688315 volatility | |
|---|---|
| 688315 Average Weekly Movement | 10.0% |
| Life Sciences Industry Average Movement | 10.0% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 688315's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688315's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2,144 | Ruiqiang Li | www.novogene.com |
Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus CR, a gene coverage for hereditary cancer screening; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples.
Novogene Co., Ltd. Fundamentals Summary
| 688315 fundamental statistics | |
|---|---|
| Market cap | CN¥5.85b |
| Earnings (TTM) | CN¥187.24m |
| Revenue (TTM) | CN¥2.09b |
31.2x
P/E Ratio2.8x
P/S RatioIs 688315 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688315 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.09b |
| Cost of Revenue | CN¥1.21b |
| Gross Profit | CN¥885.56m |
| Other Expenses | CN¥698.32m |
| Earnings | CN¥187.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 42.33% |
| Net Profit Margin | 8.95% |
| Debt/Equity Ratio | 0% |
How did 688315 perform over the long term?
See historical performance and comparison